April 2021
Psilocybin vs. Escitalopram Phase II Trial Inconclusive
The trial was not designed to test whether psilocybin is equivalent to escitalopram.
Timeline of Psychedelic Events
December 2020
Synthesis of 5-MeO-DMT Succinate
This effort makes the compound available for clinical trials.
November 2020
Aeruginascin Discovered in Psilocybe Cubensis
This study highlights the importance of understanding the chemical composition of magic mushrooms, including all the active molecules, not just psilocybin.
November 2020
Team Publishes SAR of 17 Psilocybin Analogs
The research team was led by Dr. Adam Klein
October 2020
Numinus Legally Culitvates Magic Mushrooms in Canada
This is the first time a Canadian company has legally cultivated and harvested psychedelic mushrooms since the 1970s.
September 2020
First Crystal Structure of LSD on 5-HT2A Receptor
The discovery reported by Kim at al. in the journal Cell sheds light on how compounds interact with and activate this canonical receptor.
September 2020
UC Berkeley Opens Center for the Science of Psychedelics
To begin, the center will focus on researching the effects of psilocybin.
August 2020
First Clinical Trial Combining LSD and MDMA
MindMed and Liechti Lab join forces for a first-of-its-kind psychedelic clinical trial.
August 2020
Canada’s Health Minister Grants Section 56 Exemptions for Four Late-Stage Cancer Patients
Patty Hajdu approves exemption applications filed by patients who received support and assistance from non-profit organization TheraPsil.
August 2020
Scientists Solve the Crystal Structures of the Iodide Salts of DMPT and DMALT
DMPT and DMALT are structural analogs of the quaternary tryptammonium toad secretion bufotenidine and the magic mushroom compound aeruginascin.
August 2020
NeuroPharm Begins Clinical Trials Using Psilocybin for Treating PTSD
Until this study, research into long term mental health solutions for Veterans, EMS, and frontline personnel were virtually non-existent.
July 2020
Study Finds 4-HO-TMT is Active at the 5-HT2A Receptor
This metabolite of aeruginascin has binding affinity similar to serotonin at 5-HT2A.
July 2020
CaaMTech Solves the Crystal Structures of the Hydrofumarate Salts of EPT and MALT
EPT and MALT are synthetic analogs of the more well-known active compound found in ayahuasca, DMT (N,N-dimethyltryptamine).
May 2020
CaaMTech Partners With NIH to Study Synthetic Tryptamines
This collaboration will study a full spectrum of pharmacological effects of several synthetic tryptamine compounds.
April 2020
Scientists Solve the Crystal Structure of the Freebase of 5-MeO-DALT
This crystal structure of 5-MeO-DALT is essential to understanding its physical properties and for studying its activity at receptors by using modeling studies.
April 2020
Scientists Solve Two Crystal Structures of Norpsilocin
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.
April 2020
Researchers Genetically Engineer Yeast to Produce Psilocybin and Related Tryptamines
This research provides a method for producing meaningful amounts of psilocybin analogs for scientific study and downstream applications.
April 2020
MindMed and Liechti Lab Announce LSD “Off-Switch” Technology
This technology may help ease some of the concerns surrounding psychedelic therapy.
February 2020
UK Agency Rejects Spravato (Esketamine) Nasal Spray
UK Health Technology Assessment body raised questions over the clinical and cost-effectiveness of the drug.
February 2020
Researchers Develop Synthetic Method for Making Psilocybin Derivatives
The synthesis method represents the first meaningful access to these compounds for scientific research.
February 2020
Study Finds Norpsilocin is More Potent Than Psilocin at 5-HT2A
This is the first scientific evidence that anything but psilocybin or psilocin could potentially contribute to the pharmacology of magic mushrooms.
February 2020
Study Finds Baeocystin is Not a Psychedelic Drug
Baeocystin did not cause the head twitch response in mice, meaning it does not activate the 5-HT2A receptor.
January 2020
Medical University of South Carolina Launches Psychedelic Research Center
Dr. Michael Mithoefer of the Department of Psychiatry and Behavioral Sciences will lead the center.
December 31, 2019
COMPASS Pathways Awarded Patent for Psilocybin Formulation COMP360
The scope and validity of the patent will depend on how x-ray diffraction data is interpreted.
December 22, 2019
Ram Dass Dies
The spiritual teacher and psychedelic researcher/advocate was 88 years old.
December 2019
Scientists Engineer E. Coli to Produce Psilocybin
The authors say this work is “a significant step towards demonstrating the feasibility of industrial production of biologically-derived psilocybin.”
December 2019
New Zealand University Receives Approval for LSD Microdosing Study
This study is focusing on the effects of psychedelics in everyday life.
December 2019
Silo Wellness Introduces First Magic Mushroom Nasal Spray
Nasal spray formulations like this could offer precision dosing of a spectrum of psychedelic mushroom compounds to consumers.
December 2019
New Cannabinoid Discovered in Cannabis sativa: (-)-trans-Δ9-THCP
Tetrahydrocannabiphorol could account for the pharmacological properties of some cannabis varieties.
November 2019
Study Finds ALD-52, 1P-LSD, and 1B-LSD Are Prodrugs of LSD
The data showed that ALD-52, 1P-LSD, and 1B-LSD were very weak partial agonists at the human 5-HT2A compared to LSD.
November 2019
New Magic Mushroom Compounds Identified
Researchers isolate ayahuasca-like compounds known as ß-carbolines from several species of Psilocybe.
November 2019
Quantified Citizen Launches World’s First Psychedelic Microdosing Study Mobile App
The data from the study will help generate hypotheses for future research.
November 2019
Scientists Solve Magic Mushroom Bluing Mystery
“…the blue color is due to a heterogeneous mixture of quinoid psilocyl oligomers, primarily coupled via C-5."
October 2019
Scientists Solve the Crystal Structure of 4-HO-DPT
This new solvate form opens to door to understanding its physical properties and testing its activity at biological receptors.
September 2019
Johns Hopkins Medicine Opens Center for Psychedelic and Consciousness Research
The distinguished psychedelic researcher Dr. Roland Griffiths is directing operations at the center.
September 2019
Johns Hopkins Starts Psilocybin Clinical Trial to Treat Anorexia Nervosa
Anorexia has phenomenological parallels to anxiety and addiction, both of which have been shown to improve with psilocybin-assisted interventions.
September 2019
September 2019
Scientists Solve the Crystal Structure of the Fumarate Salts of DMT and Psilocin Derivatives
The new crystalline fumarate salts of MiPT and 4-HO-MiPT could be used to modulate the effects of compounds in a drug formulation.
July 2019
Scientists Solve the Crystal Structure of MPT
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
June 4, 2019
Oakland, CA Decriminalizes the Cultivation and Possession of Some Psychedelics
The effort was led by the group Decriminalize Nature Oakland.
June 4, 2019
Scientists Find 1,000 Year Old Shaman Pouch Containing Traces of Psychedelics
The 1,000 year old ritual bundle was found in the Andes.
May 7, 2019
Denver Votes to Deprioritize the Enforcement of Psilocybin Mushroom Offenses
Personal use and possession of psilocybin mushrooms has become a low priority for Denver law enforcement.
May 2019
New Crystalline Form of Psilacetin Discovered
This new solvate of psilacetin could provide new properties like solubility, leading to new opportunities for formulating drugs.
May 2019
Researchers Synthesize 6-Methylated Congeners of Psilocybin
These new compounds will give scientists a better understanding of how serotonin-based psychedelics work.
April 26, 2019
Imperial College London Opens World’s First Center for Psychedelic Research
The new Imperial Centre for Psychedelic Research is the first of its kind in the world.
March 25, 2019
Scientists Publish the Crystal Structure of 4-AcO-DMT Fumarate
This is the crystal structure of the fumarate salt of psilacetin which was described by David Nichols and Steward Frescas of Purdue University in 1999.
March 2019
Studies Find 5-MeO-DMT Improves Symptoms of Anxiety and Depression
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
March 2019
Study Finds Sub-Acute and Sustained Benefits from a Single Inhalation of Toad Secretions
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.
February 2019
FDA Approves Esketamine for TRD
The treatment is in the form of a nasal spray containing ketamine.
January 2019
Study Confirms Psilocin Binding to 5-HT2A Receptor Causes the Psilocybin Psychedelic Experience
Researchers used PET scans, blood psilocin levels, and subjective effects to verify that psilocin binding to 5-HT2A receptors causes the psychedelic experience.
November 2018
Researchers at Johns Hopkins University School of Medicine Call for Rescheduling Psilocybin
Researchers at the Johns Hopkins School of Medicine call for psilocybin to be reclassified from a Schedule I controlled substance to Schedule IV after clearing phase III clinical trials.
October 2018
Atai Life Sciences Raises $25 Million
German entrepreneur and investor Christian Angermayer creates Atai Life Sciences and raises $25 million to study the therapeutic effects of psychedelic drugs on depression and other mental illnesses.
October 2018
FDA Gives Psilocybin Breakthrough Therapy Designation for TRD
The US Food and Drug Administration (FDA) has granted breakthrough designation for psilocybin-assisted therapy.
August 2018
FDA Approves Psilocybin for Treatment-Resistant Depression (TRD)
The UK life science company COMPASS Pathways receives FDA approval for a clinical trial using psilocybin to treat treatment-resistant depression.
July 2018
COMPASS Pathways Makes 20,000 Does of Psilocybin
COMPASS Pathways synthesizes 20,000 doses of psilocybin for use in clinical trials.
July 2018
Researchers Find Psilocybin in the Animal Kingdom for the First Time
Researchers find psilocybin in the animal kingdom for the first time.
June 2018
FDA Approves Epidiolex for Treating Some Epileptic Seizures
Epidiolex is the first FDA-approved drug containing cannabidiol (CBD).
May 2018
“How to Change Your Mind” by Michael Pollan is Published
Food author Michael Pollan changes his mind and his life and puts psychedelics back in the spotlight.
April 2018
Study Finds Psilocybin Subjective Experiences are Unique to Patients Needs
Four cancer patients treated with psilocybin-assisted therapy had different subjective experiences during their treatment, particularly with relation to their spiritual and/or psychological needs.
April 2018
Natural Speech Analytics and AI Can Tell if Psilocybin Therapy Was Successful in Treating Depression
A study showed that natural speech analytics can tell if someone is depressed and if psilocybin was successful in treating their depression.
February 2018
Study Shows Making Psilocybin Gives an Evolutionary Advantage To Mushrooms
Researchers find gene clusters that suggest making psilocybin gave mushroom a fitness advantage in natural selection.
February 2018
NYU Begins Psilocybin-Alcoholism Study
The NYU School of Medicine starts a clinical trial to assess the effects of psilocybin-assisted therapy on people with alcohol use disorder.
February 2018
Researchers Find DXM Has Different Effects Than Psilocybin
Study shows psilocybin produces greater "visual, mystical-type, insightful, and musical experiences" while dextromethorphan (DXM) causes greater feelings of disembodiment.
February 2018
Study Finds Psilocybin Improves Facial Emotion Processing and Increases Feelings of Pleasure
Researchers find psilocybin improves the ability to process emotional faces and increases feelings of pleasure.
February 2018
Study Finds Psilocybin Alters Information Processing via 5-HT2A Receptor
Using psilocybin, researchers determined that the altered information processing in the brains of people with psychosis and schizophrenia may be related to 5-hydroxytryptophan receptors.
January 2018
Study Finds Quality of the Psychedelic Experience is Important for Effective Psilocybin Therapy
Study finds that the quality of psychedelic experience from psilocybin can predict how effective therapy will be for a patient being treated for treatment-resistant depression.
January 2018
Study Finds Psilocybin Increases ‘Nature-Relatedness’ and the Effect is Long-Lasting
Preliminary study indicates patients using psilocybin to treat treatment-resistant depression are more in touch with nature and have fewer authoritarian political views.
December 2017
Depressed Patients Successfully Treated Using Psilocybin-Assisted Therapy
Researchers successfully treat depressed patients with psilocybin-assisted therapy and can use responses from their amygdala to predict treatment success..
December 2017
Scientists Develop PCR Method for Detecting and Identifying P. cubensis
A new test method is developed to detect and identify the DNA of Psilocybin cubensis.
December 2017
Pharmacokinetic Study Finds 25 mg Dose of Psilocybin Equals Oral Dose of About 0.3 mg/kg
Researchers determine that psilocybin is safe for use in people with mild to moderate renal impairment and doses up to 0.6 mg/kg result in no serious side effects.
November 1, 2017
“Psychedelic Medicine” is Published
"The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca"
October 2017
Study Finds Psilocybin With Meditation Produces Long-Lasting Positive Changes in Attitudes and Behaviors
Researchers find that using meditation and other spiritual practices along with psilocybin produces long-lasting positive changes in psychological functioning and prosocial attitudes and behaviors.
October 2017
Johns Hopkins Study Finds Psilocybin ‘Bad Trips’ May Be Caused by Neuroticism
Researchers find that "bad trips" from psilocybin mushrooms may be caused by neuroticism.
September 2017
Norpsilocin is Discovered
German researchers identify norpsilocin, a new natural product of Psilocybe cubensis that originates from baeocystin.
September 2017
Study Finds Psilocybin Increases Feelings of Empathy
Study finds that psilocybin enhances emotional empathy but not moral behavior.
September 2017
German Researchers Discover New Psilocybe Enzyme
A study further characterizes the four enzymes Psilocybe uses to make psilocybin and also finds a new class of Psilocybe enzyme.
August 2017
FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD
MDMA-assisted psychotherapy is a novel treatment package that combines psychotherapeutic techniques with three administrations of MDMA as a pharmacological adjunct.
July 2017
Johns Hopkins/NYU Psilocybin Clergy Study Begins
Two dozen clergy members start taking controlled doses of psilocybin as part of a study conducted by Johns Hopkins University and New York University.
January 2017
Article Reviews Metabolism of Psilocybin and Psilocin
Researchers discuss how the body metabolizes psilocybin and review all the major and minor metabolites.
January 2017
Study Reveals the Crystal Structure of LSD Bound to the Human 5-HT2B Receptor
This structure reveals some reasons for the long-lasting effects of LSD and gives insight into the role of receptor signaling.
November 2016
NYU Study Finds Psilocybin Benefits Patients With Cancer-Related Stress
Study shows psilocybin used in conjunction with psychotherapy "produced rapid, robust and enduring anxiolytic and antidepressant effects in patients with cancer-related psychological stress."
November 2016
Study Finds Long-lasting Positive Benefits for Cancer Patients Using Psilocybin
Researchers at Johns Hopkins University School of Medicine find psilocybin causes substantial and sustained decreases in anxiety and depression in patients with life-threatening cancer.
October 28, 2016
- October 30, 2016
Detroit Entheogenic Conference is Held
The Detroit Entheogenic Conference is held.
August 18, 2016
- August 21, 2016
Telluride Mushroom Fesival is Held
The Telluride Mushroom Festival is held in Telluride, Colorado.
July 2016
Feasibility Study Finds Psilocybin Effective for Treatment-Resistant Depression
UK researchers find from an open-label feasibility study that using psilocybin with psychological support is effective for treatment-resistant depression.
July 2016
Chemists Isolate 10 Compounds from Psilocybe merdaria
Researchers isolate 10 compounds from Psilocybe merdaria including two new ones.
June 3, 2016
- June 5, 2016
ICPR 2016 is Held
The 2016 Interdisciplinary Conference on Psychedelics Research (ICPR) is held in Amsterdam, the Netherlands.
April 26, 2016
Human Brain Visualized Under the Influence of LSD
For the first time, researchers see the human brain under the influence of LSD using various state-of-the-art neuroimaging techniques.
January 2016
Austria Decriminalizes Psilocybin Mushrooms
Possession of psilocybin mushrooms is decriminalized in Austria.
October 2015
Study Finds Psilocybin Improves Mood via the Amygdala
A study shows that psilocybin is associated with improving a person's mood and it does so by decreasing the activity of the amygdala.
September 20, 2015
First Psilocybin Global Day of Action is Held
The first annual Global 9/20 Psilocybin Mushroom Day of Action takes place.
September 18, 2015
- September 20, 2015
Women & Entheogens Conference is Held
The Women & Entheogens Conference is held in Cleveland, OH.
August 12, 2015
Russia Bans Reddit For Post on Growing Psilocybin Mushrooms
Russia bans the Reddit website after a thread discusses how to grow psilocybin mushrooms.
January 13, 2015
Study Finds Psilocybin is Effective For Treating Alcoholism
The first proof-of-concept study is conducted examining psilocybin-assisted treatment for alcoholism.
October 29, 2014
Study Reveals How Psilocybin Changes Communication Patterns in the Brain
Psilocybin disrupts the communication patterns in the brain, but there's still order.
September 11, 2014
Study Finds Psilocybin is Effective for Treating of Tobacco Addiction
Researchers conduct a safety/feasibility study using psilocybin as an adjunct for quitting smoking.
August 2013
Mouse Study Shows Psilocybin May Be Effective for Treating PTSD
Study finds the fear response in mice goes away quicker on low doses of psilocybin compared to higher doses and the authors suggest exploring its use for treating PTSD and other conditions.
November 2012
Washington is the First US State to Legalize Marijuana
Washington Initiative 502 legalized marijuana use by adults age 21 and over.
February 7, 2012
fMRI Sees the Effects of Psilocybin on the Human Brain
Researchers find that psilocybin changes blood flow, communication pathways, and activity in the brain, enabling "a state of unconstrained cognition."
February 2012
Study Identifies Other Variables That Impact the Effects of Psilocybin
A study from the University of Zurich finds several non-dosage related variables play a key role in the effects psilocybin has on humans.
May 18, 2011
“The Psychedelic Explorer’s Guide” by James Fadiman is Published
Fadiman's groundbreaking guide on psychedelics for spiritual, therapeutic, and problem-solving use.
April 2011
Pilot Study Tests the Efficacy and Safety of MDMA for Treating PTSD
This was the first completed clinical trial evaluating MDMA for use in therapy.
January 19, 2011
DEA Puts 5-MeO-DMT on Schedule I
US Drug Enforcement Administration Puts 5-MeO-DMT on Schedule I.
2011
Study Finds Psilocybin Helps Cancer Patients With Anxiety
Pilot study finds that psilocybin reduces anxiety and improves mood in patients with advanced stage cancer and anxiety.
2009
Czech Republic Decriminalizes Psilocybin
Possession of up to 40 psilocybin mushrooms is decriminalized in the Czech Republic.
December 6, 2008
Entheogenesis Australis Symposium is Held
The Entheogenesis Australis Symposium is held at Melbourne University.
December 2008
The Netherlands Sets Limits on Fresh and Dried Psilocybin Mushrooms
The Netherlands prohibits the possession of over 5.0 g of fresh or 0.5 g of dry psychoactive mushrooms.
September 2008
Finland Outlaws Psilocybe Mushrooms
New section added to the penal code in Finland prohibits growing or attempting to grow Psilocybe mushrooms.
May 30, 2008
Researchers Find Mystical Experiences from Psilocybin Have Enduring Positive Effects
Researchers at Johns Hopkins University find psilocybin-induced mystical experiences retained their meaning and significance 14 months after the study.
April 29, 2008
Albert Hofmann Dies
The famous discoverer of LSD was 101 years old.
November 2006
Study Shows Psilocybin is Safe and Effective for Treating OCD
Researchers find psilocybin is safe, tolerable, and effective for treating obsessive-compulsive disorder.
July 2006
Study Finds Psilocybin Produces Mystical Experiences
A study shows psilocybin gave study participants "experiences similar to spontaneously occurring mystical experiences."
June 2006
Study Finds Psilocybin May Help Treat Cluster Headaches
Survey results published in Neurology show both psilocybin-containing mushrooms and LSD may reduce severity and frequency of cluster headaches.
January 31, 2006
Ireland Bans Fresh Psilocybin Mushrooms
Ireland makes unprepared psilocybin mushrooms illegal.
2006
Reserchers Define the Chemical Structure of Aeruginascin
Its chemical structure is closely related to the frog skin toxin bufotenidine.
July 18, 2005
UK Bans Fresh Psilocybin Mushrooms
The new UK Drugs Act 2005 goes into effect, banning fresh psilocybin mushrooms.
June 14, 2005
New Mexico Court Rules Growing Psilocybin Mushrooms for Personal Use is Not Considered “Manufacturing of a Controlled Substance”
New Mexico court rules growing psilocybin mushrooms for personal use is not the same as "manufacturing of a controlled substance."
March 2004
Heffter Study Finds Psilocybin Has Orderly Dose- and Time-Dependent Effects
Double-blind, placebo-controlled study finds psilocybin has orderly dose- and time-dependent effects that begin about 20-40 minutes after ingestion, peak at 60-90 minutes, and diminish over the next 60-90 minutes.
June 2002
Japan Outlaws Psilocybin Mushrooms
Japanese government makes it illegal to use, produce, traffic, grow, and/or possess psilocybin mushrooms.
2002
UK Law Makes it Legal to Possess Unprepared Psilocybin Mushrooms
Possession and sale of unprepared psilocybin mushrooms become legal in the UK
July 2001
Portugal Decriminalizes All Drugs
Portugal's drug policy decriminalizes the possession of all drugs providing the amount possessed is no more than a 10-day supply.
July 2001
Denmark Makes Psilocybin Mushrooms Illegal
Danish Ministry of Health makes growing, collecting, possession, sale, and processing of psilocybin mushrooms illegal.
January 16, 2001
Raichle, et al. First Describes the Brain’s Default Mode Network
The default mode network now serves as a baseline for studying brain function and how psychedelic drugs work.
2001
Germany Expands Mushroom Laws
Germany expands the scope of Executive Order 698 of 1993 to include more aspects of psilocybin mushrooms including seeds, spores, and cell cultures.
June 1999
Chemists Publish an Improved Method for Psilocybin Synthesis
An improved synthesis method for psilocybin is published.
June 1999
Nichols Publishes Synthesis of New Psilocin Prodrug
Dr. Nichols presents the synthesis of the fumarate salt of psilacetin. This new method is easier and less expensive than synthesizing psilocybin.
December 1, 1998
Vollenweider Finds Psychotic Effects of Psilocybin Happen via 5-HT2 Receptors
Researchers find the psychosis produced from psilocybin in humans is due to activation of serotonin 2A receptors.
January 22, 1998
Belgium Outlaws Hallucinogenic Mushrooms
Royal Decree in Belgium prohibits the possession and sale of hallucinogenic mushrooms.
1998
Amanda Feilding Founds the Beckley Foundation
The Foundation works to reform global drug policy and support scientific research into psychoactive substances.
November 1997
Sweden Adds Psilocybin to Schedule I
Sweden adds Psilocybe semilanceata to their schedule I drug list as a narcotic.
June 18, 1997
Iowa Court Rules Florida v. Fiske Does Not Apply Because Defendant Knew Mushrooms Would Be Used to Make Psilocybin
Iowa Supreme Court rules that the State of Florida v Fiske does not apply in the case of a man who knew the mushrooms he picked were going to be used to make psilocybin.
May 1997
PET Scans Show the Human Brain Under the Influence of Psilocybin
Swiss researchers suggest the psychosis induced by psilocybin can be used to study the role of the serotonin 2 receptor in schizophrenia.
1997
“TiHKAL: The Continuation” is Published
Alexander and Ann Shulgin publish "TiHKAL: The Continuation."
October 1996
“Psilocybin Mushrooms of the World: An Identification Guide” is Published
This book is a landmark, detailed guide for mushroom hunters.
May 31, 1996
Timothy Leary Dies
Timothy Leary dies at age 75.
1996
Canadian Controlled Drugs and Substances Act Begins
Canada enacts the Controlled Drugs and Substances Act which places psilocybin and psilocin on their schedule III drug list.
June 1995
Indiana Court Rules Florida v. Fiske Does Not Apply Because Defendant Knew Mushrooms Contained Psilocybin
Indiana Court of Appeals rules that Florida v. Fiske does not apply in the case of a man found with dried psilocybin mushrooms because the defendant knew they contained psilocybin.
1995
- 1997
Studies Find Four Psilocybin Metabolites in Human Plasma and Urine
Studies find four metabolites of psilocybin in human plasma and urine using high-performance liquid chromatography (HPLC).
October 27, 1994
Shulgin’s Lab is Raided by the DEA
The DEA executed search warrants and found a number of infractions in Shulgin's lab.
February 1994
DMT Study ‘Breaks the Hiatus’ in Psychedelic Drug Testing
Researchers test the psychological effects of intravenously-administered DMT in healthy volunteers and find they begin almost immediately, peak at 90-120 seconds, and are almost completely resolved by 30 minutes.
1994
Weil and Davis Discover 5-MeO-DMT in Toad Secretions
The secretions of Bufo alvarius are toxic when taken orally but can be safely dried and smoked.
1993
Germany Prohibits Cultivation of Psilocybin Mushrooms
Germany enacts Executive Order 698 prohibiting the cultivation of psilocybin mushrooms.
January 1, 1993
Terence McKenna’s “Food of the Gods” is Published
"The Search for the Original Tree of Knowledge: A Radical History of Plants, Drugs, and Human Evolution"
1993
David Nichols Founds the Heffter Research Institute
"Advancing studies on psilocybin for treatment of addictions and other mental disorders, with the highest standards of scientific research."
October 1990
“PiHKAL: A Chemical Love Story” is Published
Alexander and Ann Shulgin publish "PiHKAL: A Chemical Love Story."
March 12, 1990
Mycology Research Center has DEA Registration Revoked for Letting Visitors Keep Psilocybin Mushrooms
A mushroom research center in Florida has its DEA license revoked for providing psilocybin mushrooms to unlicensed people.